On November 3, 2025 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, reported that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to these clinical presentations, Nurix and its collaborators will also present new mechanistic insights into resistance to Bruton’s tyrosine kinase (BTK) targeted therapies at a separate ASH (Free ASH Whitepaper) poster session, highlighting discoveries that expand the understanding of BTK biology.
Oral Presentation Details:
Title: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL): New and Updated Findings from an Ongoing Phase 1a/b Trial
Presenter: Zulfa Omer, M.D., Assistant Professor Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation
Abstract #: 86
Session Date and Time: Saturday, December 6, 2025, 9:30 a.m. – 11:00 a.m. ET
Presentation Time: 9:45 a.m. – 10:00 a.m. ET
Room: Orange County Convention Center – W224ABEF
Poster Presentation Details
Title: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study
Presenter: Scott Huntington M.D., MPH, Associate Professor of Internal Medicine (Hematology), Yale School of Medicine
Session Name: 623: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Abstract # 5359
Session Date and Time: Monday, December 8, 2025, 6:00 p.m. – 8:00 p.m. ET
Location: Orange County Convention Center – West Halls BЗ – B4
Title: Molecular and Structural Basis of Pan-Resistance to BTK Targeting Therapies via BTK A428D Mutation
Presenter: Quinlan Sievers, M.D., Ph.D. Memorial Sloan Kettering Cancer Center, New York, NY
Session Name: 641:Chronic Lymphocytic Leukemia: Basic and Translational Poster I
Abstract # 2102
Session Date and Time: Saturday, December 6, 2025, 5:30 p.m. – 7:30 p.m. ET
Location: Orange County Convention Center – West Halls BЗ – B4
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. Nurix also continues enrollment in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) of bexobrutideg in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trials can be accessed at clinicaltrials.gov.
(Press release, Nurix Therapeutics, NOV 3, 2025, View Source [SID1234659269])